Misoprostol

Generic Name: Misoprostol

Brand Names: Arthrotec, Cytotec, Mifegymiso

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₃₈O_₅

CAS Number: 59122-46-2

Unique Ingredient Identifier: 0E43V0BB57

Background: Misoprostol is a prostaglandin analog used to reduce the risk of NSAID related ulcers, manage miscarriages, prevent post partum hemorrhage, and also for first trimester abortions. The stimulation of prostaglandin receptors in the stomach reduces gastric acid secretion, while stimulating these receptors in the uterus and cervix can increase the strength and frequency of contractions and decrease cervical tone.

Misoprostol was granted FDA approval on 27 December 1988.

Indication: Misoprostol is indicated as a tablet to reduce the risk of NSAID induced gastric ulcers but not duodenal ulcers in high risk patients. Misoprostol is also formulated in combination with diclofenac to treat symptoms of osteoarthritis or rheumatoid arthritis in patients with a high risk of developing gastric ulcers. Misoprostol is used off label for the management of miscarriages, prevention of post partum hemorrhage, and is also used alone or in combination with mifepristone in other countries for first trimester abortions.

Associated Conditions: Gastric Ulcer, Incomplete Abortion, Missed Abortion, Postpartum Haemorrhage (PPH)

Associated Therapies: Induction of cervix ripening therapy, Medically induced abortion

Clinical Trials

Comparative Study Between the Roles of Intrauterine Misoprostol Versus the Sublingual Route for Prevention of Postpartum Blood Loss in Elective Cesarean Sections

Phase 1

Completed

Conditions: Postpartum Hemorrhage

Interventions: Drug: Misoprostol

First Posted Date: 2024-04-15

Last Posted Date: 2024-04-15

Lead Sponsor: Cairo University

Target Recruit Count: 192

Registration Number: NCT06364098

Locations: 🇪🇬
Faculty of medicine, Kasr Alainy, Cairo, Al Manyal, Egypt

Misoprostol Versus Oxytocin Infusion On Reducing Blood Loss During Abdominal Myomectomy

Phase 3

Recruiting

Conditions: Myoma;Uterus

Interventions: Drug: Misoprostol 200mcg Tab
Drug: Oxytocin

First Posted Date: 2024-03-22

Last Posted Date: 2024-03-22

Lead Sponsor: Cairo University

Target Recruit Count: 56

Registration Number: NCT06325501

Locations: 🇪🇬
faculty of medicine, Kasr el ainy hospital, Cairo university, Cairo, Egypt

Cervical Sliding Sign to Predict Outcome of Induction of Labor

Active, not recruiting

Conditions: Induction of Labor
Transvaginal Ultrasound: Cervical Sliding Sign

Interventions: Device: Transvaginal ultrasound
Drug: Misoprostol 200mcg Tab

First Posted Date: 2024-03-21

Last Posted Date: 2024-03-21

Lead Sponsor: Ain Shams Maternity Hospital

Target Recruit Count: 130

Registration Number: NCT06324279

Locations: 🇪🇬
Maternity hospital, ainshams university hospitals, Cairo, Egypt

Evaluation of Telemedicine Medical Abortion Service in Ecuador

Recruiting

Conditions: Pregnancy

Interventions: Drug: Misoprostol

First Posted Date: 2024-02-21

Last Posted Date: 2024-10-15

Lead Sponsor: Gynuity Health Projects

Target Recruit Count: 100

Registration Number: NCT06270056

Locations: 🇪🇨
El Comité de Derechos Sexuales y Reproductivos de Ecuador (CODESER), Ambato, Ecuador
🇪🇨
Cemoplaf, Quito, Ecuador
🇪🇨
Federación Nacional de Obstetrices y Obstetras del Ecuador (FENOE), Quito, Ecuador